Has Melinda Hakim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,507 in general payments to Melinda Hakim, MD across 113 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Melinda Hakim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Melinda Hakim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Melinda Hakim, MD

Ophthalmology · Los Angeles, CANPI 1588687867

Payments from drug & device makers

$2,507in general payments, 2019–2025

Across 113 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$388
Radius Health, Inc.$242
Amgen$205
Mannkind Corporation$197
Boehringer Ingelheim$169
Lilly USA, LLC$153
plus $1K from 29 others

What the payments were for

Food & beverage$2,507100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	20	$388
Radius Health, Inc.	8	$242
Amgen	8	$205
Mannkind Corporation	10	$197
Boehringer Ingelheim	6	$169
Lilly USA, LLC	6	$153
Zealand Pharma US, Inc.	6	$129
Bayer	5	$111
Novartis	5	$104
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$69
Clarus Therapeutics Inc.	3	$63
Dexcom, Inc.	2	$56
Kyowa Kirin, Inc.	2	$52
Xeris Pharmaceuticals, Inc.	3	$52
Pfizer	2	$49
Johnson & Johnson Vision Care, Inc.	3	$47
Corcept Therapeutics	2	$38
Arbor Pharmaceuticals, Inc.	2	$33
Neurocrine Biosciences, Inc.	1	$28
Biomarin Pharmaceutical Inc.	1	$27
Recordati_rare_diseases_inc.	1	$26
Verity Pharmaceuticals Inc.	1	$25
Akorn, Inc.	1	$25
IBSA Pharma Inc.	1	$24
Sumitomo Pharma America, Inc.	1	$24
AstraZeneca	1	$22
Sun Pharmaceutical Industries Inc.	1	$21
Chiesi USA, Inc.	1	$20
Bausch & Lomb, A Division Of Bausch Health US, LLC	1	$18
Shire North American Group Inc	1	$17
Oyster Point Pharma, Inc.	1	$16
Acella Pharmaceuticals, LLC	1	$16
Tolmar, Inc.	1	$14
Coopervision Inc.	1	$14
Alcon	1	$14

How this compares

$2,507 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California →

Medicare billing

Part B allowed, 2024

$139,514

Medicare patients

287

Services billed

1,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RestasisCyclosporine	30	$18,417
MieboPerfluorohexyloctane/Pf	11	$8,089
Alphagan PBrimonidine Tartrate	20	$4,098
Azelastine Hcl	56	$1,511
Dorzolamide-TimololDorzolamide/Timolol/Pf	14	$1,484
Travoprost	12	$1,433
Doxycycline Hyclate	17	$575
Tobramycin-DexamethasoneTobramycin/Dexamethasone	17	$535
Prednisolone Acetate	14	$463
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	26	$385
ErythromycinErythromycin Base	39	$334
Latanoprost	49	$282

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Los Angeles

Steven JacobsonLos Angeles$4.7M
David BoyerLos Angeles$4M
Firas RahhalLos Angeles$1.2M
Nicole FramLos Angeles$1.2M
Andrew MoshfeghiLos Angeles$1M
Pradeep PrasadLos Angeles$901K
Barry SeibelLos Angeles$835K
David LiaoLos Angeles$722K
Nisha AcharyaSan Francisco$33M
David WirtaNewport Beach$18.4M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →